APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brain and Central Nervous System Cancer Treatments

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Brain and Central Nervous System Cancer Treatments Market Outlook and Growth Opportunities 2026

29 December 2025213 pages

Choose your research edition.

Industry ResearchBrain and Central Nervous System Cancer Treatments Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Brain and Central Nervous System Cancer Treatments Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Brain and Central Nervous System Cancer Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brain and Central Nervous System Cancer Treatments Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Brain and Central Nervous System Cancer Treatments Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Brain and Central Nervous System Cancer Treatments market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Brain and Central Nervous System Cancer Treatments market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Brain and Central Nervous System Cancer Treatments market include Teva, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Brain and Central Nervous System Cancer Treatments market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Brain and Central Nervous System Cancer Treatments and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Brain and Central Nervous System Cancer Treatments sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Brain and Central Nervous System Cancer Treatments market size, projected growth trends, production technologies, key applications, and end-use industries.

Brain and Central Nervous System Cancer Treatments Segment by Company

Teva

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

Bayer

AbbVie

Takeda

Otsuka

Merck KGaA

Ipsen

Gilead Sciences

Eli Lilly

Eisai

Celgene

Bristol-Myers Squibb

Biogen Idec

AstraZeneca

Astellas

Amgen

Brain and Central Nervous System Cancer Treatments Segment by Type

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Chemotherapy

Targeted Therapy

Others

Brain and Central Nervous System Cancer Treatments Segment by Application

Brain Cancer

Spinal Cord Cancer

Others

Brain and Central Nervous System Cancer Treatments Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Brain and Central Nervous System Cancer Treatments status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Brain and Central Nervous System Cancer Treatments market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Brain and Central Nervous System Cancer Treatments significant trends, drivers, influence factors in global and regions.

6. To analyze Brain and Central Nervous System Cancer Treatments competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brain and Central Nervous System Cancer Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brain and Central Nervous System Cancer Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brain and Central Nervous System Cancer Treatments.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Brain and Central Nervous System Cancer Treatments market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Brain and Central Nervous System Cancer Treatments industry.

Chapter 3: Detailed analysis of Brain and Central Nervous System Cancer Treatments manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Brain and Central Nervous System Cancer Treatments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Brain and Central Nervous System Cancer Treatments in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Brain and Central Nervous System Cancer Treatments Industry Trends Table 2. Brain and Central Nervous System Cancer Treatments Industry Drivers Table 3. Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges Table 4. Brain and Central Nervous System Cancer Treatments Industry Restraints Table 5. Global Brain and Central Nervous System Cancer Treatments Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Brain and Central Nervous System Cancer Treatments Revenue Share by Company (2021-2026) Table 7. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Company (2021-2026) Table 9. Global Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Brain and Central Nervous System Cancer Treatments Company Ranking, (2024-2026) & (USD Million) Table 11. Global Brain and Central Nervous System Cancer Treatments Key Company Manufacturing Base & Headquarters Table 12. Global Brain and Central Nervous System Cancer Treatments Company, Product Type & Application Table 13. Global Brain and Central Nervous System Cancer Treatments Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Brain and Central Nervous System Cancer Treatments by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immunotherapy (Biologic Therapy) Table 18. Significant Companies of Hormonal Therapy Table 19. Significant Companies of Chemotherapy Table 20. Significant Companies of Targeted Therapy Table 21. Significant Companies of Others Table 22. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Type (2021-2026) Table 26. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Type (2027-2032) Table 27. Global Brain and Central Nervous System Cancer Treatments Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Brain and Central Nervous System Cancer Treatments Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Brain and Central Nervous System Cancer Treatments Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Type (2021-2026) Table 31. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Brain Cancer Table 33. Significant Companies of Spinal Cord Cancer Table 34. Significant Companies of Others Table 35. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Application (2021-2026) Table 39. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Application (2027-2032) Table 40. Global Brain and Central Nervous System Cancer Treatments Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Brain and Central Nervous System Cancer Treatments Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Brain and Central Nervous System Cancer Treatments Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Application (2021-2026) Table 44. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Application (2027-2032) Table 45. Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2026) & (K Units) Table 47. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2021-2026) Table 48. Global Brain and Central Nervous System Cancer Treatments Sales by Region (2027-2032) & (K Units) Table 49. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2027-2032) Table 50. Global Brain and Central Nervous System Cancer Treatments Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Brain and Central Nervous System Cancer Treatments Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Region (2021-2026) Table 53. Global Brain and Central Nervous System Cancer Treatments Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Region (2027-2032) Table 55. Global Brain and Central Nervous System Cancer Treatments Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Brain and Central Nervous System Cancer Treatments Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Brain and Central Nervous System Cancer Treatments Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Brain and Central Nervous System Cancer Treatments Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 60. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2026) Table 61. Global Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 62. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2027-2032) Table 63. Global Brain and Central Nervous System Cancer Treatments Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Brain and Central Nervous System Cancer Treatments Sales Value Market Share by Country (2021-2026) Table 65. Global Brain and Central Nervous System Cancer Treatments Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Brain and Central Nervous System Cancer Treatments Sales Value Market Share by Country (2027-2032) Table 67. Teva Company Information Table 68. Teva Business Overview Table 69. Teva Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Teva Brain and Central Nervous System Cancer Treatments Product Portfolio Table 71. Teva Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio Table 76. Sanofi Recent Development Table 77. Johnson & Johnson Company Information Table 78. Johnson & Johnson Business Overview Table 79. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio Table 81. Johnson & Johnson Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio Table 86. Novartis Recent Development Table 87. Merck & Co. Company Information Table 88. Merck & Co. Business Overview Table 89. Merck & Co. Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio Table 91. Merck & Co. Recent Development Table 92. Roche Company Information Table 93. Roche Business Overview Table 94. Roche Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Roche Brain and Central Nervous System Cancer Treatments Product Portfolio Table 96. Roche Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 101. Pfizer Recent Development Table 102. Bayer Company Information Table 103. Bayer Business Overview Table 104. Bayer Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 106. Bayer Recent Development Table 107. AbbVie Company Information Table 108. AbbVie Business Overview Table 109. AbbVie Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio Table 111. AbbVie Recent Development Table 112. Takeda Company Information Table 113. Takeda Business Overview Table 114. Takeda Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio Table 116. Takeda Recent Development Table 117. Otsuka Company Information Table 118. Otsuka Business Overview Table 119. Otsuka Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio Table 121. Otsuka Recent Development Table 122. Merck KGaA Company Information Table 123. Merck KGaA Business Overview Table 124. Merck KGaA Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio Table 126. Merck KGaA Recent Development Table 127. Ipsen Company Information Table 128. Ipsen Business Overview Table 129. Ipsen Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 131. Ipsen Recent Development Table 132. Gilead Sciences Company Information Table 133. Gilead Sciences Business Overview Table 134. Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio Table 136. Gilead Sciences Recent Development Table 137. Eli Lilly Company Information Table 138. Eli Lilly Business Overview Table 139. Eli Lilly Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio Table 141. Eli Lilly Recent Development Table 142. Eisai Company Information Table 143. Eisai Business Overview Table 144. Eisai Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio Table 146. Eisai Recent Development Table 147. Celgene Company Information Table 148. Celgene Business Overview Table 149. Celgene Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio Table 151. Celgene Recent Development Table 152. Bristol-Myers Squibb Company Information Table 153. Bristol-Myers Squibb Business Overview Table 154. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio Table 156. Bristol-Myers Squibb Recent Development Table 157. Biogen Idec Company Information Table 158. Biogen Idec Business Overview Table 159. Biogen Idec Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio Table 161. Biogen Idec Recent Development Table 162. AstraZeneca Company Information Table 163. AstraZeneca Business Overview Table 164. AstraZeneca Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio Table 166. AstraZeneca Recent Development Table 167. Astellas Company Information Table 168. Astellas Business Overview Table 169. Astellas Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio Table 171. Astellas Recent Development Table 172. Amgen Company Information Table 173. Amgen Business Overview Table 174. Amgen Brain and Central Nervous System Cancer Treatments Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 176. Amgen Recent Development Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Brain and Central Nervous System Cancer Treatments Distributors List Table 180. Brain and Central Nervous System Cancer Treatments Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Brain and Central Nervous System Cancer Treatments Product Image Figure 2. Global Brain and Central Nervous System Cancer Treatments Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 4. Global Brain and Central Nervous System Cancer Treatments Sales (2021-2032) & (K Units) Figure 5. Global Brain and Central Nervous System Cancer Treatments Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Brain and Central Nervous System Cancer Treatments Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immunotherapy (Biologic Therapy) Image Figure 10. Hormonal Therapy Image Figure 11. Chemotherapy Image Figure 12. Targeted Therapy Image Figure 13. Others Image Figure 14. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Type (2021-2032) Figure 17. Global Brain and Central Nervous System Cancer Treatments Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Brain and Central Nervous System Cancer Treatments Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Type (2021-2032) Figure 20. Brain Cancer Image Figure 21. Spinal Cord Cancer Image Figure 22. Others Image Figure 23. Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Application (2021-2032) Figure 26. Global Brain and Central Nervous System Cancer Treatments Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Brain and Central Nervous System Cancer Treatments Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Application (2021-2032) Figure 29. Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Brain and Central Nervous System Cancer Treatments Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 34. North America Brain and Central Nervous System Cancer Treatments Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Brain and Central Nervous System Cancer Treatments Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Brain and Central Nervous System Cancer Treatments Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 40. South America Brain and Central Nervous System Cancer Treatments Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Brain and Central Nervous System Cancer Treatments Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Brain and Central Nervous System Cancer Treatments Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Brain and Central Nervous System Cancer Treatments Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others
Applications
  • Brain Cancer
  • Spinal Cord Cancer
  • Others
Companies covered
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • Bayer
  • AbbVie
  • Takeda
  • Otsuka
  • Merck KGaA
  • Ipsen
  • Gilead Sciences
  • Eli Lilly
  • Eisai
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • AstraZeneca
  • Astellas
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  4. 1.2.2 Global Brain and Central Nervous System Cancer Treatments Sales Volume (2021-2032)
  5. 1.2.3 Global Brain and Central Nervous System Cancer Treatments Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Brain and Central Nervous System Cancer Treatments Market Dynamics
  1. 2.1 Brain and Central Nervous System Cancer Treatments Industry Trends
  2. 2.2 Brain and Central Nervous System Cancer Treatments Industry Drivers
  3. 2.3 Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges
  4. 2.4 Brain and Central Nervous System Cancer Treatments Industry Restraints
3 Brain and Central Nervous System Cancer Treatments Market by Company
  1. 3.1 Global Brain and Central Nervous System Cancer Treatments Company Revenue Ranking in 2025
  2. 3.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Company (2021-2026)
  3. 3.3 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Company (2021-2026)
  4. 3.4 Global Brain and Central Nervous System Cancer Treatments Average Price by Company (2021-2026)
  5. 3.5 Global Brain and Central Nervous System Cancer Treatments Company Ranking (2024-2026)
  6. 3.6 Global Brain and Central Nervous System Cancer Treatments Company Manufacturing Base and Headquarters
  7. 3.7 Global Brain and Central Nervous System Cancer Treatments Company Product Type and Application
  8. 3.8 Global Brain and Central Nervous System Cancer Treatments Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Brain and Central Nervous System Cancer Treatments Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Brain and Central Nervous System Cancer Treatments Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Brain and Central Nervous System Cancer Treatments Market by Type
  1. 4.1 Brain and Central Nervous System Cancer Treatments Type Introduction
  2. 4.1.1 Immunotherapy (Biologic Therapy)
  3. 4.1.2 Hormonal Therapy
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Targeted Therapy
  6. 4.1.5 Others
  7. 4.2 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type
  8. 4.2.1 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Brain and Central Nervous System Cancer Treatments Sales Value by Type
  12. 4.3.1 Global Brain and Central Nervous System Cancer Treatments Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Brain and Central Nervous System Cancer Treatments Sales Value by Type (2021-2032)
  14. 4.3.3 Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Type (2021-2032)
5 Brain and Central Nervous System Cancer Treatments Market by Application
  1. 5.1 Brain and Central Nervous System Cancer Treatments Application Introduction
  2. 5.1.1 Brain Cancer
  3. 5.1.2 Spinal Cord Cancer
  4. 5.1.3 Others
  5. 5.2 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application
  6. 5.2.1 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Brain and Central Nervous System Cancer Treatments Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Brain and Central Nervous System Cancer Treatments Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Brain and Central Nervous System Cancer Treatments Sales Value by Application
  10. 5.3.1 Global Brain and Central Nervous System Cancer Treatments Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Brain and Central Nervous System Cancer Treatments Sales Value by Application (2021-2032)
  12. 5.3.3 Global Brain and Central Nervous System Cancer Treatments Sales Value Share by Application (2021-2032)
6 Brain and Central Nervous System Cancer Treatments Regional Sales and Value Analysis
  1. 6.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2032)
  3. 6.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021-2026
  4. 6.2.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region (2027-2032)
  5. 6.3 Global Brain and Central Nervous System Cancer Treatments Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Brain and Central Nervous System Cancer Treatments Sales Value by Region (2021-2032)
  7. 6.4.1 Global Brain and Central Nervous System Cancer Treatments Sales Value by Region: 2021-2026
  8. 6.4.2 Global Brain and Central Nervous System Cancer Treatments Sales Value by Region (2027-2032)
  9. 6.5 Global Brain and Central Nervous System Cancer Treatments Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  12. 6.6.2 North America Brain and Central Nervous System Cancer Treatments Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  15. 6.7.2 Europe Brain and Central Nervous System Cancer Treatments Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Brain and Central Nervous System Cancer Treatments Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  21. 6.9.2 South America Brain and Central Nervous System Cancer Treatments Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Brain and Central Nervous System Cancer Treatments Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Brain and Central Nervous System Cancer Treatments Sales Value Share by Country, 2025 VS 2032
7 Brain and Central Nervous System Cancer Treatments Country-level Sales and Value Analysis
  1. 7.1 Global Brain and Central Nervous System Cancer Treatments Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Brain and Central Nervous System Cancer Treatments Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  4. 7.3.1 Global Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026)
  5. 7.3.2 Global Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032)
  6. 7.4 Global Brain and Central Nervous System Cancer Treatments Sales Value by Country (2021-2032)
  7. 7.4.1 Global Brain and Central Nervous System Cancer Treatments Sales Value by Country (2021-2026)
  8. 7.4.2 Global Brain and Central Nervous System Cancer Treatments Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Brain and Central Nervous System Cancer Treatments Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Brain and Central Nervous System Cancer Treatments Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Brain and Central Nervous System Cancer Treatments Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Brain and Central Nervous System Cancer Treatments Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Brain and Central Nervous System Cancer Treatments Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio
  60. 8.10.5 Takeda Recent Developments
  61. 8.11 Otsuka
  62. 8.11.1 Otsuka Company Information
  63. 8.11.2 Otsuka Business Overview
  64. 8.11.3 Otsuka Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio
  66. 8.11.5 Otsuka Recent Developments
  67. 8.12 Merck KGaA
  68. 8.12.1 Merck KGaA Company Information
  69. 8.12.2 Merck KGaA Business Overview
  70. 8.12.3 Merck KGaA Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio
  72. 8.12.5 Merck KGaA Recent Developments
  73. 8.13 Ipsen
  74. 8.13.1 Ipsen Company Information
  75. 8.13.2 Ipsen Business Overview
  76. 8.13.3 Ipsen Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio
  78. 8.13.5 Ipsen Recent Developments
  79. 8.14 Gilead Sciences
  80. 8.14.1 Gilead Sciences Company Information
  81. 8.14.2 Gilead Sciences Business Overview
  82. 8.14.3 Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio
  84. 8.14.5 Gilead Sciences Recent Developments
  85. 8.15 Eli Lilly
  86. 8.15.1 Eli Lilly Company Information
  87. 8.15.2 Eli Lilly Business Overview
  88. 8.15.3 Eli Lilly Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio
  90. 8.15.5 Eli Lilly Recent Developments
  91. 8.16 Eisai
  92. 8.16.1 Eisai Company Information
  93. 8.16.2 Eisai Business Overview
  94. 8.16.3 Eisai Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio
  96. 8.16.5 Eisai Recent Developments
  97. 8.17 Celgene
  98. 8.17.1 Celgene Company Information
  99. 8.17.2 Celgene Business Overview
  100. 8.17.3 Celgene Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio
  102. 8.17.5 Celgene Recent Developments
  103. 8.18 Bristol-Myers Squibb
  104. 8.18.1 Bristol-Myers Squibb Company Information
  105. 8.18.2 Bristol-Myers Squibb Business Overview
  106. 8.18.3 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio
  108. 8.18.5 Bristol-Myers Squibb Recent Developments
  109. 8.19 Biogen Idec
  110. 8.19.1 Biogen Idec Company Information
  111. 8.19.2 Biogen Idec Business Overview
  112. 8.19.3 Biogen Idec Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio
  114. 8.19.5 Biogen Idec Recent Developments
  115. 8.20 AstraZeneca
  116. 8.20.1 AstraZeneca Company Information
  117. 8.20.2 AstraZeneca Business Overview
  118. 8.20.3 AstraZeneca Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio
  120. 8.20.5 AstraZeneca Recent Developments
  121. 8.21 Astellas
  122. 8.21.1 Astellas Company Information
  123. 8.21.2 Astellas Business Overview
  124. 8.21.3 Astellas Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio
  126. 8.21.5 Astellas Recent Developments
  127. 8.22 Amgen
  128. 8.22.1 Amgen Company Information
  129. 8.22.2 Amgen Business Overview
  130. 8.22.3 Amgen Brain and Central Nervous System Cancer Treatments Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio
  132. 8.22.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Brain and Central Nervous System Cancer Treatments Value Chain Analysis
  2. 9.1.1 Brain and Central Nervous System Cancer Treatments Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Brain and Central Nervous System Cancer Treatments Sales Mode & Process
  6. 9.2 Brain and Central Nervous System Cancer Treatments Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Brain and Central Nervous System Cancer Treatments Distributors
  9. 9.2.3 Brain and Central Nervous System Cancer Treatments Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst